vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Twin Vee PowerCats, Co. (VEEE). Click either name above to swap in a different company.

Twin Vee PowerCats, Co. is the larger business by last-quarter revenue ($3.0M vs $1.8M, roughly 1.7× INVO Fertility, Inc.). Twin Vee PowerCats, Co. runs the higher net margin — -85.6% vs -150.5%, a 64.9% gap on every dollar of revenue. On growth, Twin Vee PowerCats, Co. posted the faster year-over-year revenue change (60.4% vs 22.6%). INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-1.9M). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs -24.3%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Twin Vee PowerCats Co. is a leading manufacturer of high-performance recreational power catamaran boats. The company offers a diverse lineup of catamaran models suited for leisure cruising, fishing, water sports, and commercial marine use, serving customers primarily across North America, with a growing distribution network in global coastal markets.

IVF vs VEEE — Head-to-Head

Bigger by revenue
VEEE
VEEE
1.7× larger
VEEE
$3.0M
$1.8M
IVF
Growing faster (revenue YoY)
VEEE
VEEE
+37.8% gap
VEEE
60.4%
22.6%
IVF
Higher net margin
VEEE
VEEE
64.9% more per $
VEEE
-85.6%
-150.5%
IVF
More free cash flow
IVF
IVF
$104.3K more FCF
IVF
$-1.8M
$-1.9M
VEEE
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
-24.3%
VEEE

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IVF
IVF
VEEE
VEEE
Revenue
$1.8M
$3.0M
Net Profit
$-2.6M
$-2.6M
Gross Margin
3.7%
Operating Margin
-93.1%
-87.7%
Net Margin
-150.5%
-85.6%
Revenue YoY
22.6%
60.4%
Net Profit YoY
-62.2%
-119.0%
EPS (diluted)
$-0.77
$-1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
VEEE
VEEE
Q4 25
$3.0M
Q3 25
$1.8M
$3.4M
Q2 25
$1.9M
$4.8M
Q1 25
$1.6M
$3.6M
Q4 24
$1.7M
$1.9M
Q3 24
$1.4M
$2.9M
Q2 24
$1.8M
$4.3M
Q1 24
$1.6M
$5.3M
Net Profit
IVF
IVF
VEEE
VEEE
Q4 25
$-2.6M
Q3 25
$-2.6M
$-2.8M
Q2 25
$-5.3M
$-1.7M
Q1 25
$-17.4M
$-1.6M
Q4 24
$-3.6M
$-1.2M
Q3 24
$-1.6M
$-3.0M
Q2 24
$-2.2M
$-4.5M
Q1 24
$-1.6M
$-2.3M
Gross Margin
IVF
IVF
VEEE
VEEE
Q4 25
3.7%
Q3 25
-1.3%
Q2 25
13.8%
Q1 25
35.2%
14.9%
Q4 24
41.4%
-57.6%
Q3 24
31.0%
-5.0%
Q2 24
53.1%
4.7%
Q1 24
45.3%
5.3%
Operating Margin
IVF
IVF
VEEE
VEEE
Q4 25
-87.7%
Q3 25
-93.1%
-81.0%
Q2 25
-160.4%
-35.2%
Q1 25
-1042.1%
-46.5%
Q4 24
-202.0%
-224.9%
Q3 24
-90.7%
-107.3%
Q2 24
-100.9%
-107.7%
Q1 24
-95.7%
-48.2%
Net Margin
IVF
IVF
VEEE
VEEE
Q4 25
-85.6%
Q3 25
-150.5%
-80.4%
Q2 25
-283.6%
-34.8%
Q1 25
-1060.1%
-44.6%
Q4 24
-211.3%
-62.7%
Q3 24
-113.8%
-103.7%
Q2 24
-122.2%
-104.4%
Q1 24
-101.3%
-44.3%
EPS (diluted)
IVF
IVF
VEEE
VEEE
Q4 25
$-1.19
Q3 25
$-0.77
$-1.23
Q2 25
$-13.30
$-0.87
Q1 25
$-12.53
$-1.08
Q4 24
$14.86
$-3.51
Q3 24
$-15.11
$-2.64
Q2 24
$-22.39
$-3.09
Q1 24
$-7.55
$-1.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
VEEE
VEEE
Cash + ST InvestmentsLiquidity on hand
$1.4M
Total DebtLower is stronger
$2.0M
$499.9K
Stockholders' EquityBook value
$5.8M
$13.5M
Total Assets
$18.8M
$16.2M
Debt / EquityLower = less leverage
0.34×
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
VEEE
VEEE
Q4 25
$1.4M
Q3 25
$2.7M
Q2 25
$6.0M
Q1 25
$4.9M
Q4 24
$7.5M
Q3 24
$11.1M
Q2 24
$14.9M
Q1 24
$17.1M
Total Debt
IVF
IVF
VEEE
VEEE
Q4 25
$499.9K
Q3 25
$2.0M
$499.9K
Q2 25
$4.8M
$499.9K
Q1 25
$499.9K
Q4 24
$7.5M
$499.9K
Q3 24
$499.9K
Q2 24
$499.9K
Q1 24
$499.9K
Stockholders' Equity
IVF
IVF
VEEE
VEEE
Q4 25
$13.5M
Q3 25
$5.8M
$15.9M
Q2 25
$2.6M
$18.6M
Q1 25
$3.3M
$17.7M
Q4 24
$12.7M
$19.2M
Q3 24
$-23.3K
$17.4M
Q2 24
$1.4M
$19.6M
Q1 24
$10.2K
$22.3M
Total Assets
IVF
IVF
VEEE
VEEE
Q4 25
$16.2M
Q3 25
$18.8M
$18.9M
Q2 25
$19.3M
$22.4M
Q1 25
$31.7M
$23.6M
Q4 24
$46.4M
$25.9M
Q3 24
$17.0M
$30.1M
Q2 24
$17.8M
$33.8M
Q1 24
$17.3M
$36.5M
Debt / Equity
IVF
IVF
VEEE
VEEE
Q4 25
0.04×
Q3 25
0.34×
0.03×
Q2 25
1.83×
0.03×
Q1 25
0.03×
Q4 24
0.59×
0.03×
Q3 24
0.03×
Q2 24
0.03×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
VEEE
VEEE
Operating Cash FlowLast quarter
$-1.8M
$-1.7M
Free Cash FlowOCF − Capex
$-1.8M
$-1.9M
FCF MarginFCF / Revenue
-101.6%
-62.5%
Capex IntensityCapex / Revenue
0.5%
4.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-9.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
VEEE
VEEE
Q4 25
$-1.7M
Q3 25
$-1.8M
$-2.6M
Q2 25
$-1.7M
$-745.6K
Q1 25
$-3.5M
$-1.7M
Q4 24
$-617.4K
$-2.3M
Q3 24
$-640.8K
$-2.4M
Q2 24
$-1.5M
$-482.1K
Q1 24
$-260.6K
$-1.7M
Free Cash Flow
IVF
IVF
VEEE
VEEE
Q4 25
$-1.9M
Q3 25
$-1.8M
$-3.1M
Q2 25
$-1.7M
$-1.5M
Q1 25
$-3.6M
$-2.6M
Q4 24
$-696.3K
$-3.6M
Q3 24
$-3.7M
Q2 24
$-1.5M
$-2.2M
Q1 24
$-310.3K
$-3.7M
FCF Margin
IVF
IVF
VEEE
VEEE
Q4 25
-62.5%
Q3 25
-101.6%
-91.2%
Q2 25
-92.6%
-30.6%
Q1 25
-216.9%
-71.0%
Q4 24
-40.6%
-192.8%
Q3 24
-128.8%
Q2 24
-82.3%
-51.0%
Q1 24
-19.7%
-70.9%
Capex Intensity
IVF
IVF
VEEE
VEEE
Q4 25
4.6%
Q3 25
0.5%
14.0%
Q2 25
0.5%
14.9%
Q1 25
0.9%
22.9%
Q4 24
4.6%
68.8%
Q3 24
0.0%
45.8%
Q2 24
3.0%
39.9%
Q1 24
3.2%
37.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons